GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » EBITDA per Share

MetaStat (MetaStat) EBITDA per Share : $-0.53 (TTM As of Feb. 2018)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat EBITDA per Share?

MetaStat's EBITDA per Share for the three months ended in Feb. 2018 was $-0.16. Its EBITDA per Share for the trailing twelve months (TTM) ended in Feb. 2018 was $-0.53.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for MetaStat's EBITDA per Share or its related term are showing as below:

MTST's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 6.05
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

MetaStat's EBITDA for the three months ended in Feb. 2018 was $-0.92 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


MetaStat EBITDA per Share Historical Data

The historical data trend for MetaStat's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat EBITDA per Share Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.69 -4.39 -2.34 -0.60 -0.55

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.05 -0.14 -0.19 -0.16

MetaStat EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MetaStat's EBITDA per Share for the fiscal year that ended in Feb. 2018 is calculated as

EBITDA per Share(A: Feb. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.973/5.425
=-0.55

MetaStat's EBITDA per Share for the quarter that ended in Feb. 2018 is calculated as

EBITDA per Share(Q: Feb. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.919/5.924
=-0.16

EBITDA per Share for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MetaStat  (OTCPK:MTST) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


MetaStat EBITDA per Share Related Terms

Thank you for viewing the detailed overview of MetaStat's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines